Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting

NEW YORK–(BUSINESS WIRE)– class= »bwalignl »>
Regulatory News:

Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene edited CAR T-cells (UCART), today announced that abstracts
regarding the Company’s allogeneic, off-the-shelf, CAR T programs have
been accepted for presentation at the 58th American Society of
Hematology (ASH) Annual Meeting and Exposition. The meeting will be held
December 3-6, 2016 in San Diego.

Oral presentations:

• 765 Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong
  Overall Survival of AML Patient-Derived Xenografts
  

  https://ash.confex.com/ash/2016/webprogram/Paper97033.html

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Program:
Oral and Poster Abstracts
Type: Oral
Session: 616. Acute
Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging
Immune-Based Therapies for AML
Monday, December 5, 2016: 11:00 AM
San
Diego Ballroom AB (Marriott Marquis San Diego Marina)

Monica L. Guzman, PhD¹, Mayumi
Sugita, MD^1*, Hongliang Zong, MD, PhD^1*,
Nathan Ewing-Crystal^1*, Vicenta Trujillo-Alonso^1*,
Nuria Mencia-Trinchant, PhD^1*, Linda Lam^1*,
Nicole M. Cruz, MD¹, Roman Galetto, PhD^2*,
Agnès Gouble, PhD^2*, Duane C Hassane, PhD¹,
Julianne Smith, PhD² and Gail J. Roboz^3
1Division
of Hematology and Medical Oncology, Department of Medicine, Weill
Cornell Medical College, New York, NY
²Cellectis
SA, Paris, France
³Weill Cornell Medical
College, New York, NY

• 381 Preclinical Evaluation of Allogeneic Anti-Bcma Chimeric Antigen
  Receptor T Cells with Safety Switch Domains and Lymphodepletion
  Resistance for the Treatment of Multiple Myeloma
  

  https://ash.confex.com/ash/2016/webprogram/Paper90155.html

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
Program:
Oral and Poster Abstracts
Type: Oral
Session: 652. Myeloma:
Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel
Immune Approaches for Myeloma Therapy
Sunday, December 4, 2016:
12:30 PM
Grand Hall B (Manchester Grand Hyatt San Diego)

Bijan Boldajipour, PhD^1*, Roman
Galetto, PhD^2*, Cesar Sommer, PhD^1*,
Thomas Pertel, PhD^1*, Julien Valton, PhD^3*,
Yoon Park, PhD^1*, Annabelle Gariboldi^2*,
Amy Chen^1*, Tao Geng^1*,
Hong H Dong^1*, Gregory R Boucher^1*,
Thomas J Van Blarcom, PhD^1*, Javier
Chaparro-Riggers, PhD^1*, Arvind Rajpal, PhD^1*,
Julianne Smith, PhD³, Tracy Kuo, PhD^1*
and Barbra Sasu, PhD^1
1Pfizer
Inc., South San Francisco, CA
²Cellectis
SA, Paris, France
³Cellectis Inc., New
York, NY

Poster presentation:

• 4039 Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the
  Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  

  https://ash.confex.com/ash/2016/webprogram/Paper95092.html

Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation
Program:
Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemia:
Novel Therapy, excluding Transplantation: Poster III
Monday,
December 5, 2016, 6:00 PM-8:00 PM
Hall GH (San Diego
Convention Center)

Tianyu Cai, PhD^1*, Roman Galetto, PhD^2*,
Agnès Gouble, PhD^2*, Julianne Smith, PhD²,
Antonio Cavazos, MS^1*, Sergej Konoplev, MD, PhD³,
Andrew A. Lane, MD, PhD⁴, Monica L. Guzman, PhD⁵,
Hagop M. Kantarjian, MD¹, Naveen Pemmaraju, MD¹
and Marina Konopleva, MD, PhD^1
1Department
of Leukemia, The University of Texas MD Anderson Cancer Center, Houston,
TX
²Cellectis SA, Paris, France
³Department
of Hematopathology, The University of Texas MD Anderson Cancer Center,
Houston, TX
⁴Dana-Farber Cancer Institute,
Boston, MA
⁵Division of Hematology and
Medical Oncology, Department of Medicine, Weill Cornell Medical College,
New York, NY

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 16 years of expertise
in genome engineering – based on its flagship TALEN® products and
meganucleases and pioneering electroporation PulseAgile technology – to
create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets.

In June 2014, Cellectis and Pfizer began collaborating on a joint
clinical development program for CAR-T therapies, in the field of
oncology, directed at numerous targets selected by Pfizer.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161107006632/en/